Novo Nordisk shares tumbled 23 per cent, their biggest one-day fall in 22 years, after a trial of its weight-loss drug CagriSema fell short of expectations.
Novo Nordisk shares tumbled 23 per cent, their biggest one-day fall in 22 years, after a trial of its weight-loss drug CagriSema fell short of expectations.